Ascendis Pharma A/S (ASND)

Ascendis Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Cash & Equivalents	812.26	616.04	559.54	392.16	444.77	446.27
Short-Term Investments	-	-	-	7.28	290.69	235.8
Cash & Short-Term Investments	812.26	616.04	559.54	399.44	735.46	682.06
Cash Growth	64.41%	10.10%	40.08%	-45.69%	7.83%	-5.11%
Accounts Receivable	206.51	141.33	166.28	35.87	11.91	2.2
Other Receivables	17.6	16.36	11.16	19.9	13.72	20.99
Receivables	224.1	157.7	177.44	55.77	25.63	23.19
Inventory	310.58	301.53	295.61	208.93	130.67	75.41
Prepaid Expenses	43.47	33.72	28.27	38.58	31.72	25.23
Total Current Assets	1,390	1,109	1,061	702.72	923.47	805.89
Property, Plant & Equipment	135.69	146.48	98.71	110.63	129.1	126.05
Long-Term Investments	30.48	32.53	13.58	5.69	30.42	145.91
Goodwill	-	3.5	3.5	3.5	-	3.5
Other Intangible Assets	3.68	0.22	0.53	0.92	4.83	1.78
Other Long-Term Assets	26.49	10.87	2.32	2.13	1.92	1.81
Total Assets	2,286	1,303	1,179	825.59	1,090	1,085

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Accounts Payable	103.92	90.66	96.39	94.57	101.03	59.42
Accrued Expenses	-	-	-	41.18	31.99	29.95
Current Portion of Long-Term Debt	65.43	466.09	476.05	407.1	399.19	-
Current Portion of Leases	-	20.44	15.48	14.17	13.79	7
Current Income Taxes Payable	12.66	6.43	1.22	2.3	5.49	0.2
Current Unearned Revenue	2.78	4.94	0.94	1.18	-	2.6
Other Current Liabilities	280.1	480.83	317.78	176.02	165.29	1.19
Total Current Liabilities	464.89	1,069	907.86	736.51	716.78	100.36
Long-Term Debt	236.36	254.17	287.53	138.38	-	-
Long-Term Leases	148.29	131.09	77.55	84.62	95.4	97.97
Long-Term Unearned Revenue	-	1.12	5	5.95	14.21	2.96
Long-Term Deferred Tax Liabilities	-	9.62	7.26	5.83	-	-
Total Liabilities	849.53	1,465	1,285	971.28	826.39	201.29

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Common Stock	8.89	8.32	8.15	7.75	7.68	7.65
Additional Paid-In Capital	3,300	2,531	2,444	2,123	2,113	2,108
Retained Earnings	-1,878	-2,700	-2,560	-2,277	-1,860	-1,236
Treasury Stock	-0.07	-0.08	-0.11	-0.15	-0.15	-0.02
Comprehensive Income & Other	6.16	-1.76	1.78	0.72	3.45	3.78
Shareholders' Equity	1,436	-162.82	-105.71	-145.7	263.35	883.64
Total Liabilities & Equity	2,286	1,303	1,179	825.59	1,090	1,085

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Total Debt	450.07	871.79	856.62	644.27	508.38	104.96
Net Cash (Debt)	362.19	-255.75	-297.07	-244.83	234.57	684.66
Net Cash Growth	-	-	-	-	-65.74%	-7.74%
Net Cash Per Share	5.72	-4.22	-5.13	-4.35	4.18	12.50
Filing Date Shares Outstanding	65.67	61.38	59.84	56.61	56.04	56.78
Total Common Shares Outstanding	65.67	61.38	59.84	56.61	56.04	56.78
Working Capital	925.52	39.59	153	-33.79	206.69	705.53
Book Value Per Share	21.87	-2.65	-1.77	-2.57	4.70	15.56
Tangible Book Value	1,433	-166.53	-109.73	-150.12	258.52	878.36
Tangible Book Value Per Share	21.82	-2.71	-1.83	-2.65	4.61	15.47
Machinery	-	37.62	32.91	38.86	-	25.77
Leasehold Improvements	-	7.05	20.3	19.38	-	18.07

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 22, 2026

Data Sources Report a data error